{"id":"W2587995109","doi":"10.1182/blood.v116.21.283.283","title":"Results of a Pivotal Phase 2 Study of Brentuximab Vedotin (SGN-35) in Patients with Relapsed or Refractory Hodgkin Lymphoma","year":2010,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":51,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; CD30; Internal medicine; Oncology; Phases of clinical research; Refractory (planetary science); Antibody-drug conjugate; Gastroenterology; Anaplastic large-cell lymphoma; Lymphoma; Chemotherapy; Immunology; Antibody; Monoclonal antibody","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003048923,0.001308032,0.001750791,0.0002775251,0.0003005502,0.00074712,0.0005386013,0.0008532327,0.001932315],"category_scores_gemma":[0.00137245,0.0004789981,0.0009465285,0.000241909,0.0005634535,0.0006256686,0.0002619672,0.001972727,0.000478112],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006694273,"about_ca_system_score_gemma":0.0008817633,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004963782,"about_ca_topic_score_gemma":0.001122459,"domain_scores_codex":[0.9993719,0.0003960774,0.00003043746,0.00007553429,0.00004612777,0.00007996811],"domain_scores_gemma":[0.9990551,0.00023654,0.0001704858,0.0000719702,0.00007793993,0.0003881195],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7877617,0.03724601,0.01624857,0.0009342271,0.00205672,0.0004587006,0.0005298198,0.002815618,0.05549166,0.000200557,0.004059239,0.09219714],"study_design_scores_gemma":[0.497911,0.4629987,0.02963421,0.00004150002,0.000864381,0.0004818939,0.00006881743,0.001095885,0.003941002,0.0001280032,0.002803967,0.00003058882],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.994903,0.002040977,0.0003633724,0.0002534393,0.00006848602,0.0009184233,0.0006192359,0.00004869288,0.0007844188],"genre_scores_gemma":[0.9951344,0.0009441724,0.0007355641,0.0004068863,0.0001171601,0.0006691373,0.001308977,0.00001562037,0.0006680203],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003048923,"threshold_uncertainty_score":0.01612449,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.00971226627271056,"score_gpt":0.2612806839358168,"score_spread":0.2515684176631062,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}